Hecubine
Hecubine is a monoterpene indole alkaloid found in Ervatamia ocinalis. Hecubine activates TREM2 expression, reduces LPS (HY-D1056)-stimulated inammatory cytokines (TNF-α、IL-6、IL-1β) overexpression, as well as suppresses the levels of TLR4-, MyD88-, MAPK/PI3K/AKT- and NF-κB-related proteins. Hecubin also exhibits antioxidative effect, reduces ROS production and activates of the Nrf2/HO-1 pathway. Hecubine rescues LPS-induced behavioral deficits in zebrash larvae. Hecubine can be used for the research of neural inflammation-associated central nervous system diseases.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 62874-52-6
- Formel: C20H26N2O
- Molecular Weight:310.43
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
TREM-2 |
HO-1 |
IL-1β |
IL-6 |
In Vitro
Hecubine directly binds to purified TREM2 protein with a binding affinity of -7.07 ± 0.03 kcal/mol[1].
Hecubine (25 μM; 1 h) directly interacts with TREM2 in BV2 microglial cells, increasing the protein's thermal stability by shifting its Tm by 6.4 ± 0.7 °C[1].
Hecubine (0.7-50 μM; 1 h pretreatment, followed by 24 h LPS stimulation) inhibits LPS (HY-D1056)-induced NO production in BV2 microglial cells with an IC50 of ~6 μM, achieving 52.1%, 64.6%, and 73.8% inhibition at 6, 12, and 25 μM respectively[1].
Hecubine (6-25 μM; 1 h pretreatment, followed by 24 h LPS stimulation) suppresses LPS-induced production of pro-inflammatory mediators (PGE2, TNF-α, IL-6, IL-1β) and restores IL-10 levels in BV2 microglial cells, with maximal effects at 25 μM including reducing PGE2 to 15.3% and IL-6 to <8.8% of LPS-treated levels[1].
Hecubine (6-25 μM; 1 h pretreatment, followed by LPS stimulation) upregulates TREM2 expression, downregulates TLR4/MyD88 signaling, inhibits MAPK/PI3K/AKT and NF-κB pathway activation, and reduces iNOS/COX-2 expression in LPS-stimulated BV2 microglial cells, with 25 μM Hecubine suppressing p38/AKT phosphorylation and NF-κB p65 nuclear translocation by ~45%, ~45.6%, and ~40.1% respectively[1].
Hecubine (6-25 μM; 1 h pretreatment, followed by LPS stimulation) inhibits LPS-induced ROS production in BV2 microglial cells in a dose-dependent manner[1].
Hecubine (6-25 μM; 1 h pretreatment, followed by LPS stimulation; or 1 h treatment alone) activates the Nrf2/HO-1 antioxidant pathway in BV2 microglial cells, with 25 μM Hecubine increasing Nrf2 and HO-1 expression by 4.45-fold and 8.69-fold respectively in LPS-stimulated cells, and increasing expression of both proteins in a dose-dependent manner in unstimulated cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS-stimulated mouse BV2 microglial cells
-
Concentration:6, 12, 25 μM
-
Incubation Time:1 h pretreatment, followed by 24 h LPS stimulation
-
Result:Reduced LPS-induced PGE2 production to 15.3% of the LPS-treated group at 25 μM.
Suppressed LPS-induced TNF-α, IL-6, and IL-1β secretion, with 25 μM decreasing IL-6 levels to <8.8% of the LPS-treated group.
Reversed the LPS-induced decrease in the anti-inflammatory cytokine IL-10 in a dose-dependent manner.
-
Cell Line:LPS-stimulated mouse BV2 microglial cells
-
Concentration:6, 12, 25 μM
-
Incubation Time:1 h pretreatment, followed by LPS stimulation
-
Result:Dose-dependently increased TREM2 protein expression.
Inhibited LPS-induced increases in TLR4, MyD88, iNOS, and COX-2 protein expression.
Suppressed LPS-induced phosphorylation of p38, JNK, ERK 1/2, AKT, IKKα/β, IκBα, and NF-κB p65.
At 25 μM, inhibited p38 and AKT phosphorylation to ~55% and ~54.4% of LPS-treated levels respectively, and reduced LPS-induced NF-κB p65 nuclear translocation to ~59.9% of LPS-treated levels.
Increased Nrf2 and HO-1 protein expression by 4.45-fold and 8.69-fold at 25 μM respectively.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Zebrash larvae wild-type (4 days post-fertilization larvae)[1]
-
Dosage:6 μM; 12 μM; 25 μM
-
Administration:continuous exposure; 24 hours prior to LPS injection
-
Result:Significantly increased the total swimming distance of LPS-injected larvae, reversing LPS-induced behavioral deficits.
Suppressed LPS-induced NO production and reduced LPS-induced Iba1 protein expression at 25 μM.
Dose-dependently inhibited LPS-induced increases in iNOS protein and mRNA expression, as well as IL-1β protein expression.
Reversed LPS-induced upregulation of TNF-α, IL-1β, and IL-6 mRNA expression.
Reduced LPS-induced ROS accumulation.
Increased TREM2, Nrf2 and HO-1 protein expression in LPS-injected larvae.
Chemical Information
-
CAS. Nr. 62874-52-6
-
Molecular Weight 310.43
-
Formel C20H26N2O
-
SMILES
CC[C@@]12[C@@]3([H])[C@](C[N@](CCC4=C(N(C5=CC=CC=C54)C)CC2)C1)([H])O3
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)